Attorneys Involved Xarelto Lawsuits Set Sites On August Trial In MississippiSouthern Med Law

Xarelto Lawsuits Selected For Trials Allege Life-Threatening Bleeding Event Similar To Those In Thousands Of Other Blood Thinner Complaints.

As more than 17,000 federal Xarelto lawsuits move forward in litigation, a third Xarelto bellwether trial is scheduled for August 7 in the District of Mississippi. This is the first trial held outside of the District of Louisiana where federal Xarelto lawsuits are consolidated in a multidistrict litigation (MDL) against Xarelto manufacturers, Bayer and Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. Thousands of plaintiffs allege the Xarelto blood thinner causes severe internal bleeding, hemorrhagic stroke, gastrointestinal bleeding, and other bleeding complications and even death. (In Re: Xarelto Products Liability Litigation)

“We continue to receive calls from men and women who experienced serious bleedings events after taking Xarelto and want to know what legal options are available to them,” says Dr. François Blaudeau, founder of Southern Med Law.

The firm’s Xarelto attorneys represent men and women who developed life-threatening bleeding events after taking blood thinners. If you or a loved one experienced serious internal bleeding or other complications allegedly associated with Xarelto, please contact Southern Med Law to learn more about your legal rights. You can arrange for a free, no-obligation Xarelto lawsuit evaluation by calling Southern Med Law today at 205-547-5525 or visit www.southernmedlaw.com for more information and to fill out a contact form.

The next bellwether trial for Xarelot lawsuits involves a Mississippi woman who suffered gastrointestinal bleeding after using Xarelto to treat blood clots, the lawsuit said. (Xarelto Lawsuits Case No. 2:15-cv-03469, In Re: Xarelto Products Liability Litigation) Bellwether trials are seen as “test trials” which help both sides assess how juries respond to plaintiffs’ claims. The outcome of bellwether trials may also help the parties determine whether to settle similar lawsuits pending in litigation.

Xarelto (rivaroxaban) is approved by the U.S. Food and Drug Administration (FDA) to prevent strokes, deep vein thrombosis, pulmonary embolism, and blood clots in patients with atrial fibrillation not caused by a heart valve problem. Xarelto and other blood thinners like Pradaxa (dabigatran) and Eliquis (apixaban) are new oral anticoagulants promoted as being more convenient for patients than warfarin (Coumadin, Jantoven), the only FDA-approved blood thinner since1954 used to prevent stroke in patients with atrial fibrillation. With the new blood thinners, routine blood monitoring is not required for patients as it is for warfarin. Additionally, the new anticoagulants do not interfere with patients’ diets. Should bleeding occur, warfarin uses vitamin K to reverse the anticoagulant’s effects. Xarelto and Eliquis do not have an FDA-approved reversal agent should a patient experience adverse bleeding side effects. Pradaxa uses Praxbind to reverse bleeding side effects.
[fda.gov/Drugs/NewsEvents/ucm405148.htm]
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm]

The Xarelto lawsuits pending in the MDL accuse Bayer Healthcare and Janssen Pharmaceuticals of failing to warn doctors and their patients about the safety risks associated with Xarelto, including the potential for uncontrollable bleeding episodes. The Xarelto complaints also contend the defendants failed to disclose that Xarelto does not have an antidote to reverse adverse bleeding events which can lead to death. A wrongful death lawsuit joined the MDL in June involving an Oregon woman who took Xarelto between May 2015 and August 2015. In July 2015, the woman started coughing up blood, and then suffered anemia, an alveolar hemorrhage and a subarachnoid bleed, according to the lawsuit. Unfortunately, the woman died in August 2015.(Xarelto Case No. 2:17-cv-06252, In Re: Xarelto Products Liability Litigation, Xarelto lawsuits No. 2592)